We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The test’s ability to predict how well bladder cancer patients will respond to therapy allows for “timely interventions that could result in more favorable outcomes,” the company said.
This sort of action against CROs is something rarely seen from the FDA; the last occurrence was in April 2016 and involved another Indian CRO, Semler Research.